A growing number of inherited neurodegenerative disorders, including Huntington's disease, have been shown to be caused by the expansion of CAG/polyglutamine repeats. The molecular mechanism underlying these disorders, however, has yet to be clarified. We and others previously demonstrated that caspase-8 was activated by proteolysis in association with the expression of extended polyglutamine. Here, we further analyzed the selectivity of caspases in the process mediated by extended polyglutamine. Among upstream caspases, caspase-10, a close homolog of caspase-8, was also proteolytically activated, but caspase-9 was not. Caspase-8 and -10 were recruited into nuclear aggregates of extended polyglutamine, where at least a fraction of these caspases was converted to the activated forms. Caspase-8 and -10 were co-immunoprecipitated with polyglutamine only when the polyglutamine was pathologically extended, whereas caspase-2, -3, -6, -7 and -9 were not co-immunoprecipitated with polyglutamine regardless of its size. A dominant-negative form of caspase-8 with a mutation at the catalytic cysteine residue inhibited polyglutamine-mediated nuclear apoptotic phenotype. These results suggest that caspase-8 and -10 are autoactivated as a result of close proximity of the proforms of these molecules that occurs due to aggregate formation, which reveals a novel toxic gain-offunction mechanism for the pathogenesis of CAG-repeat disorders. Cell Death and Differentiation (2001) 8, 377 ± 386.
Introduction
To date, eight neurodegenerative disorders including Huntington's disease (HD) and dentatorubral pallidoluysian atrophy (DRPLA), have been shown to be caused by the expansion of CAG repeats. 1, 2 The CAG repeats are located in the coding regions of the respective responsible genes and are translated into polyglutamine. These disorders, collectively called CAG-repeat disorders or polyglutamine diseases, are characterized by neuron death in the region specific to each disease. 3 The molecular mechanism underlying these disorders has yet to be clarified. However, accumulating evidence suggests that caspases, at least in part, are involved in the neurodegeneration.
Caspases constitute a family of cysteine proteases that play important roles in the execution of apoptosis. Each of these enzymes is synthesized as a zymogen and proteolytically activated by its own active form or other members of caspases. 4 Involvement of caspases in CAGrepeat disorders are supported by three groups of observations: (i) Some of the products of the genes responsible for CAG-repeat disorders are substrates for caspases, and their cleaved fragments carrying extended polyglutamine tend to easily form aggregates; 5 ± 8 (ii) an activated form of caspases has been detected in the affected regions of the brains of patients and of model animals as well as in cultured cells of experimental systems; 9 ± 11 and (iii) inhibition of caspases slows cell death or suppresses the apoptotic nuclear phenotype in model animals as well as in in vitro experimental systems. 10, 12 We previously demonstrated that expression of extended polyglutamine sequentially activated caspase-8 and then caspase-3. 9 Sa Â nchez et al. 10 also reported detection of the proteolytically activated form of caspase-8 in the affected brain region of HD patients. Caspase-8 (MACH/FLICE/ Mch5) was originally cloned as a protein that interacts with FADD (MORT1), a mediator of Fas (CD95/APO-1)-induced apoptosis, or as a component of death-inducing signaling complex (DISC). 13, 14 The targeted disruption of the caspase-8 gene is lethal in utero and the TNF receptors, Fas, and DR3 failed to induce cell death in embryo fibroblasts containing a disrupted caspase-8 gene. 15 To analyze the selectivity of caspases during the process of cell death mediated by extended polyglutamine and to further investigate the mechanism of caspase activation, we have analyzed the interaction of polyglutamine and various caspases. We show here that polyglutamine preferentially interacts with and activates caspase-8 and its close homolog, caspase-10 (Mch4/ FLICE2), 16, 17 and suggest a novel caspase-8-or -10-mediated cell death pathway alternative to Fas-mediated apoptosis.
Results
Among initiator caspases, caspase-8 and -10 are proteolytically activated by polyglutamine, but caspase-9 is not
We and others previously demonstrated that caspase-8 was cleaved and activated in association with the expression of extended polyglutamine. 9, 10 In the present study, we first examined whether caspase-10, a close homolog of caspase-8, was also proteolytically activated during this process. To address this question, we utilized the TC-controlled polyglutamine expression system in IGROV cells as described previously. 9 IGROV-EQ19 and IGROV-EQ56 cells express 19-and 56-stretches of polyglutamine fused with the enhanced green fluorescent protein (EGFP) (EGFP-polyQ 19 and EGFP-polyQ 56 ), respectively, when TC is removed from the culture medium. The cleaved products of caspase-8 and -10 were detected at 72 h after withdrawal of TC only in cells expressing extended polyglutamine ( Figure 1A , top and middle panels). Another apical caspase that plays an important role in apoptosis is caspase-9 (MCH6), which is activated by Apaf1 and cytochrome c released from mitochondria. 19 In contrast to caspase-8 and -10, the amount of the proform of caspase-9 remained constant and the cleaved form was not detected by 72 h after the TC withdrawal ( Figure 1A , bottom panel). The caspase-9 antibody used in this experiment was confirmed to react with the processed form of caspase-9 20 by the use of an engineered construct, caspase-9DC (amino acids 1 ± 315), in addition to the intact form ( Figure 1B) . The antibody had no cross reactivity with the intact or processed forms of caspase-3, -8, -6, or -7 ( Figure 1B , and data not shown). These results indicate that the caspase-9-mediated apoptotic pathway is not involved in polyglutamine-induced cell death.
Caspase-8 and -10 colocalize with nuclear aggregates of extended polyglutamine
Initiator caspases such as caspase-8 and -9 were reported to be autoactivated by oligomerization of the molecules 21, 22 If procaspase-8 coaggregates with polyglutamine, caspase-8 molecules are brought into close proximity and may cleave one another. To test this hypothesis, we first analyzed the subcellular localization of caspases-8 and -10 in the presence or absence of nuclear aggregates of extended polyglutamine. By immunostaining, caspase-8 and -10 were detected primarily in the cytoplasm ( Figure 2B ,E, thin arrows). However, in cells with nuclear aggregates of extended polyglutamine, these caspases were primarily detected in the nucleus, and co-localized with the aggregates ( Figure 2B , E, thick arrows, and Figure 2C , F). The specificity of the results was demonstrated by the absence of co-localization of caspase-3 and Bcl-2 with the aggregates (Figure 2G ± L). This also indicates that the nuclear signals in Figure 2B , E are not due to the leakage of green fluorescence of GFPpolyglutamine. 
Caspase-8 is activated in nuclear aggregates
To test whether caspases were activated in the nuclear aggregates, we raised antibodies that specifically react with a processed form of caspase-8 or -9. It has been demonstrated that caspase-8 and -9 are proteolytically cleaved at Asp374 and Asp315, respectively. 20, 23 Hexapeptides that precede the cleavage sites as well as an amino-terminal cysteine residue to allow coupling to keyhole limpet hemocyanin were synthesized and used as immunogens. Antisera that had been shown to have high titers against the respective antigens in ELISA were purified by immunoadsorption to the same peptides. We then analyzed the specificity of each antiserum with GST-or His 6 -tagged proteins produced in E. coli ( Figure 3A,B) . The anti-caspase-8DC antiserum recognized GST-fused caspase-8DC, which corresponds to the processed form, but not full-length caspase-8 or caspase-8DN ( Figure 3C , lanes 1 ± 3). Anti-caspase-9DC also reacted with the pseudo-processed form but not with caspase-9DN ( Figure 3D , lanes 4 and 5). These antisera did not react with other species of caspases, including caspase-7 ( Figure 3D , and data not shown). Thus, the two antisera could be used to detect processed forms of caspase-8 and -9.
We then applied the two antisera to the cells expressing extended polyglutamine and forming nuclear aggregates as in the experiments shown in Figure 2 . Activated caspase-8 was detected in nuclear aggregates containing extended polyglutamine (Figure 4A ± C). However, caspase-8 was not activated in cells without nuclear aggregates even if they express extended polyglutamine homogeneously throughout the cell ( Figure 4C , arrow). In contrast, activated caspase-9 was not detected in cells with nuclear aggregates (Figure 4D ± F). Staining with anticaspase-9DC antiserum did detect activated caspase-9 in Jurkat cells growing in the presence of staurosporine (STS) but not in the cells without the treatment ( Figure 4G , H). In addition, processed forms of caspase-9 were detected in Jurkat cell lysate when treated with STS by immunoblotting ( Figure 4I , lane 4), indicating that the green fluorescence in Figure 4H indeed demonstrates cleaved caspase-9. However, the smaller form of the processed caspase-9 was not detected by the conventional anti-caspase-9 used in Figure 1 ( Figure 4I , lane 2). Altogether, failure to detect activated caspase-9 in nuclear aggregates is not due to the inability of anti-caspase-9DC to react with its antigen in immunostaining. Therefore, based on these results, we conclude that at least a fraction of caspase-8 in the nuclear aggregates is converted into its activated form.
Polyglutamine preferentially interacts with caspase-8 in vivo
To further demonstrate the selectivity of caspases in the polyglutamine-induced processing, we performed immunoprecipitation experiments. After various caspases were tagged with a FLAG-epitope, they were transiently expressed in 293 cells together with GFP-tagged polyglutamines. Extended polyglutamine (71 repeats) easily formed large aggregates in the nucleus, whereas polyglutamine of a normal size range (19 repeats) was distributed homogeneously both in the nucleus and cytoplasm ( Figure 5A ). Immunoprecipitation experiments with the anti-FLAG antibody followed by detection by Western blotting with the anti-GFP antibody clearly showed that extended polyglutamine was specifically co-precipitated with caspase-8 among the caspases tested, and that polyglutamine with a normal size range was not ( Figure  5B ). In this experiment, caspase-8 had to have a mutation at the cysteine residue in the active center (C360S) in order to obtain a high level of expression similar to those of other caspases as reported previously. 13 Caspase-6 and -9 were not co-precipitated with polyglutamine regardless of the length of the polyglutamine. This was not due to a difference in the expression levels of the caspases, as demonstrated by Western blotting without immunoprecipitation ( Figure 5C ).
Polyglutamine selectively interacts with endogenous caspase-8 and -10
To explore the interaction under more physiological conditions, we next examined whether extended polyglutamine Figure 3 The specificity of antisera raised against the C-terminal cleavage site of caspase-8 and -9. (A) Schematic diagrams of recombinant GST-or His 6 -caspases produced in E. coli. The numbers below the boxes indicate the position of the amino acids counted from the initiation methionine. Peptides used to generate antisera corresponding to the C-terminal amino acids of the cleaved forms are indicated with the single letter code. (B) Six hundred nanograms of the purified fusion proteins were analyzed by electrophoresis on 10% SDS-polyacrylamide gels, followed by Coomassie Brilliant Blue staining. (C,D) Fifty nanograms of the indicated proteins were subjected to SDS ± PAGE, followed by Western blotting with anti-caspase-8DC (C) or anticaspase-9DC (D) antibody
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Expanded polyglutamine interacts with caspase-8 and -10 M U et al interacts with endogenous caspases. Using a conditional expression system employing IGROV cells, endogenous caspase-8 was confirmed to be co-immunoprecipitated with extended polyglutamine but not with polyglutamine of a normal size range ( Figure 6A ). Interestingly, most molecules obtained by co-immunoprecipitation were the processed form rather than the proform, which suggests that procaspase-8 recruited into the aggregates with polyglutamine rapidly undergoes proteolysis. With the converse combinations of antibodies in immunoprecipitation and Western blotting, antibodies against caspase-8 or -10 pulled down extended polyglutamine, but not polyglutamine of a normal size range ( Figure 6B ). On the other hand, endogenous caspase-2, -3, and -7 were not co-immunoprecipitated with extended polyglutamine, further demonstrating the specificity of the caspase in the interaction with polyglutamine ( Figure 6C ± G).
Anti-caspase-3 and -7 antibodies successfully immunoprecipitated the respective caspases ( Figure 6C ,D, right panels) and anti-caspase-2, -3, and -7 reacted with the respective antigens when immunoblotted ( Figure 6C ± G) . Therefore, the failure to detect interaction of polyglutamine with these caspases was not due to the inability of the antibodies to react with their antigens. All the data presented herein demonstrate that caspase-8 and -10 selectively interact with polyglutamine.
Indirect interaction of polyglutamine with the caspases
We then examined with an in vitro binding assay whether polyglutamine and caspases directly interact with each other. GST-polyglutamine fusion proteins were generated in E. coli 1 and 3) or presence of 500 nM staurosporine (lanes 2 and 4) for 6 h and Western blot analyses were performed using anti-caspase-9 (lanes 1 and 2) and anti-caspase-9DC antibodies (lanes 3 and 4)
Cell
and purified by affinity chromatography ( Figure 7A ). They were then incubated with in vitro-translated caspases labeled with [ 35 S]-methionine. Neither radio-labeled caspase-8 nor caspase-9 interacted with GST-fused polyglutamines regardless of its length under conditions in which GST-Bcl-2 was readily associated with Bax, a known heteromeric binding partner of Bcl-2 ( Figure 7B ). Therefore, it is likely that polyglutamine binds to caspase-8 and -10 via a third adaptor molecule(s).
Dominant negative caspase-8 effectively inhibits polyglutamine-mediated apoptosis
To further examine the involvement of caspase-8 in polyglutamine-mediated apoptosis, we made a construct, pFLAGCasp8(C/S), encoding protease-dead caspase-8 that has a dominant negative effect on the wild-type caspase-8. 13 As reported earlier, a pan-caspase inhibitor, z-VAD-fmk, had no effect on the aggregate formation of polyglutamine, while it significantly, although not completely, inhibited apoptosis (Table 1) . 9 Caspase-8(C/S) also inhibited apoptosis to a similar extent, although, again, had no effect on aggregate formation. This implies that caspase-8 is a major mediator of polyglutamine-mediated apoptosis.
Discussion
Two major pathways lead to the activation of effector caspases and eventually to cell death via apoptosis. One involves the release of cytochrome c from mitochondria, which, together with Apaf-1 and dATP, activates caspase-9. Another pathway involves DISC-formation, including caspase-8, at the site of death receptors such as Fas. Therefore, among at least fourteen members of the caspase family reported to date, caspase-8 and -9 are the pivotal apical caspases. This is also supported by experiments showing that the targeted disruption of each caspase resulted in seriously defective phenotypes caused by the failure to induce cell death. 15, 24, 25 Here we have demonstrated the possibility that caspase-8, but not -9, plays an important role in polyglutamine-induced cell death. However, the role of caspase-9 is not completely ruled out, because it was recently reported that caspase-9 can be activated without proteolysis, and that its activity is also regulated by phosphorylation. 20, 26 We also demonstrated here for the first time that caspase-10 also interacts with and is activated by extended polyglutamine. This finding is intriguing but not unexpected because caspase-10 (FLICE2) has a significant homology over its entire sequence (28% identity) to caspase-8. 17 The importance of caspase-10, at least in lymphocyte homeostasis, has been demonstrated recently by the discovery of inherited caspase-10 mutations in autoimmune lymphoproliferative syndrome. 27 However, the similar extents of inhibition of apoptosis by z-VAD-fmk and caspase-8(C/S) may imply that caspase-10 is not absolutely required for polyglutamine-induced apoptosis. In any case, since GST-fused polyglutamine did not interact with in vitro-translated caspase-8, it is more likely that these two The relationship between aggregate formation, particularly in the nucleus and induction of apoptosis still remains controversial. In some experiments, nuclear aggregation did not appear to be necessary for cell death. 11, 28 However, microaggregation that cannot be detected by observation under a microscope may induce caspase-8 (or -10) oligomerization and activation. It is also possible that extended polyglutamine induce both aggregate-dependent and -independent cell death. The latter may not be caspase-dependent.
In any case, it is not yet clear how polyglutamine forms aggregates exclusively in the nucleus, at least in some types of cells such as IGROV-1, 293, or PC12 (Figures 2  and 5A , and data not shown). At least, our GFP-tagged polyglutamine does not have a nuclear localization signal. In addition, further studies should address the question of whether polyglutamine and caspase-8 first bind each other in the cytoplasm and then enter the nucleus. In this case, the apoptotic process is triggered in the cytoplasm before polyglutamine enters the nucleus. The interaction is probably mediated by microaggregation or oligomerization of polyglutamine as discussed above. Alternatively, a small amount of nuclear caspase-8 interacts with polyglutaminemediated nuclear aggregates and then recruits more caspase-8. There have been several reports that demonstrate the nuclear localization of some caspases such as caspase-1, -2, -3, or -9 under certain circumstances.
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Recently, DAXX, first identified as a protein capable of binding Fas, was reported to regulate Fas-induced apoptosis from promyelocytic leukemia protein (PML) 
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Expanded polyglutamine interacts with caspase-8 and -10 M U et al oncogenic domains. 33 PML also associates with ataxin-1, a causative molecule of spinocerebellar ataxia, type 1, which is one of the CAG-repeat diseases. 34 Interestingly, DAXX has been reported to interact with caspase-8 and -10, at least in yeast two-hybrid analysis. 33 Therefore, polyglutamine-mediated activation of these proteases may be regulated by DAXX. Several other proteins have been reported to co-aggregate with polyglutamine, including 20S proteasome protein, molecular chaperones, and leucinerich acidic nuclear protein. 35, 36 Among these proteins, molecular chaperones such as Hsp40 or Hsp70 may play important roles in pathogenesis, since they have been reported to suppress polyglutamine toxicity both in Drosophila and cultured cells. 37 ± 40 Caspase-8 has been suggested to have roles distinct from mediation of death receptor-induced cell death. Defective embryonic development in caspase-8 knockout mice seems to indicate that some effect other than cell death induction (perhaps growth stimulation) is mediated by caspase-8. 15 Other evidence has shown that detachmentinduced apoptosis, also called anoikis, involves the activation of caspase-8. 41 , 42 Here we have demonstrated an additional caspase-8-and possibly -10-mediated apoptotic pathway induced by polyglutamine, where both caspases are autoactivated by co-aggregating with extended polyglutamine in the nucleus and then activate downstream caspases. This explains, at least in part, the toxic gain-of-function mechanism mediated by expanded polyglutamine.
Recently Ona et al. 12 reported that the inhibition of caspase-1 by a dominant-negative mutant of caspase-1 delays the onset or slows the progression of HD in model animals. Since caspase-1 is a proinflammatory rather than proapoptotic caspase, it is possible that this is an indirect effect of the inhibition of inflammatory responses rather than of the inhibition of apoptosis. In any case, this observation, together with ours using a dominant negative mutant of caspase-8, has potentially important implications for therapeutic intervention.
Materials and Methods

Reagents
Carbobenzoxy-Val-Ala-Asp -fluoromethyl ketone (z-VAD-fmk) was purchased from Peptide Institute Inc., Japan. Rabbit anti-caspase-3, -8, and Bcl-2 antibodies were kindly provided by Dr. JC Reed. Monoclonal antibodies against green fluorescent protein (GFP) and caspase-9 was purchased from Medical & Biological Lab., Japan. Anti-FLAG and caspase-7 monoclonal antibodies were purchased from Sigma and Transduction Lab., respectively. Rabbit polyclonal antibodies against caspase-2 and -10 (FLICE2) were from Santa Cruz Biotechnology and Millennium Biotechnology, respectively. The anti-human Fas monoclonal antibody (CH11) was purchased from Medical & Biological Laboratories, Japan.
Generation of antibodies that speci®cally recognize cleaved forms of caspase-8 and -9
Japanese white rabbits were immunized with NH 2 -CIPVETD-COOH or NH 2 -CSNPEPD-COOH peptides. These peptides contained the six amino acids that precede aspartic acid 374 of caspase-8 and aspartic acid 315 of caspase-9, respectively, in addition to an amino-terminal cysteine residue for coupling to keyhole limpet hemocyanin. The rabbits were boosted six times with the immunizing peptides over an 8-week period, and sacrificed at 10 weeks when titers against the immunizing peptide were 41 : 100 000 and 1 : 10 000, respectively (determined by ELISA and defined as the maximal dilution giving a positive response, arbitrarily set at OD 492 =0.2 using the chromogenic substrate for horseradish peroxidase). The antisera, designated as anti-caspase-8DC and anti-caspase-9DC hereafter, were affinitypurified using SulfoLink Kits (PIERCE) in which the respective immunizing peptides were immobilized on agarose.
Cell culture and transfection
The human ovarian cancer cell line, IGROV-1, and its derivatives for inducible expression of polyglutamine were previously described. 9 The human embryonic kidney cell line, 293, and human T-cell leukemia line, Jurkat, were cultured in Dulbecco's modified Eagle's medium and RPMI 1640 medium, respectively, supplemented with 10% fetal calf serum, 50 U/ml penicillin and 0.1 mg/ml streptomycin at 378C in a humidified atmosphere of 5% CO 2 and 95% air. 293 cells (2610 6 ) were transfected with a mixture of Effectene reagent (Qiagen), 3.5 mg of FLAG-tagged and 1.5 mg GFP-tagged vector. z-VAD-fmk (50 mM) was added during transfection in some experiments to enhance the expression level of transfected genes. Cell lysates were prepared 3 days after transfection using the following lysis buffer: 10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% NP40 and a cocktail of protease inhibitors.
Plasmid constructs
pEGFP-polyQ 19 and pEGFP-polyQ 56 were described previously. 9 To produce pEGFP-polyQ 71 , an ApaI-ApaI fragment carrying 71 repeats of polyglutamine was excised from pMY1247 5 and subcloned into pEGFP-C3 (Clontech). pGEX-polyQ constructs were made in pGEX-5X-3 (Amersham Pharmacia Biotech) with DNA fragments amplified by PCR with primers located in the DRPLA gene, in which 7 amino acids at the 5' end and 17 amino acids at 3' end in addition to polyglutamine were encoded. cDNAs covering the entire coding region of human caspase-6 and -9 were obtained by polymerase chain reaction coupled with reverse transcription (RT ± PCR) with fetal brain mRNA (Clontech) and primers designed based on the reported sequences. They were then subcloned into the FLAG-tag vectors pcDNA3-FLAG or pCI-FLAG (kindly provided by Dr. S Takayama) to generate pCasp6-FLAG and pFLAG-Casp9, respectively. cDNA encoding the caspase-8 prodomain was amplified by RT ± PCR as described above and subcloned into pET15b/Casp8 (kindly provided by Dr. GS Salvesen), which encodes the amino acids from Ser217 to the C terminus of caspase-8. The resulting cDNA encoding full-length caspase-8 was then excised and subcloned into pCI-FLAG to generate pFLAG-Casp8. pFLAGCasp8(C/S) was created by the PCR overlap extension technique. 18 Full-length and deletion mutants of caspase-3 (amino acids 1 ± 175), caspase-8 (amino acids 1 ± 374), and caspase-9 (amino acids 1 ± 315) were generated by PCR, subcloned into pCI-FLAG or pBluescript SK caspase-8 by pET15b/Casp8 in E. coli strain BL21(DE3)pLysS (Novagen). GST-tagged and His 6 -tagged proteins were purified by affinity chromatography using glutathione-Sepharose 4B (Amersham Pharmacia Biotech) and Ni-nitrilotriacetic acid agarose (Qiagen), respectively, according to the manufacturer's instructions.
Immunostaining and confocal microscopy
To determine the subcellular localization of target proteins, cells were cultured on chamber slides (Nalge Nunc International). After induction of transfected genes, cells were fixed at 48C for 1 h in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 for 1 h, and blocked for 1 h at RT in 5% skim milk and 1% BSA in 10 mM TrisHCl (pH 8.0), 150 mM NaCl and 0.1% Tween20. The slides were then incubated for 1 h with rabbit polyclonal antibodies recognizing caspase-3, caspase-8, caspase-8DC, caspase-9DC, caspase-10 or Bcl-2, and then with tetramethylrhodamine isothiocyanate (TRITC)-labeled anti-rabbit immunoglobulin (1 : 20) . A fluorescent image was obtained using a confocal microscope (Fluoview or GB-200, OLYMPUS, Tokyo, Japan).
In vitro translation and binding assay
The in vitro-translated proteins were prepared using the TNT-coupled reticulocyte lysate system (Promega) according to the manufacturer's recommendations. Ten microliters of the reaction mixture was used for Western blotting. For in vitro binding assays, 10 mg of GST fusion proteins immobilized on glutathione-Sepharose were mixed with 10 ml of L-[
35 S] methionine-labeled in vitro-translated proteins in 250 ml of HKM solution (10 mM HEPES (pH 7.2), 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA and 0.2% NP-40) for 2 h at 48C. Beads were washed four times before they were boiled in Laemmli buffer. Eluted proteins were analyzed by SDS ± PAGE followed by autoradiography.
Immunoprecipitation and Western blot analysis
Two hundred micrograms of total protein was immunoadsorbed with the antibody against GFP, FLAG, caspase-3, -7, -8 or -10 for 6 h at 48C, and then with protein A/G agarose (Santa Cruz Biotechnology) for 16 h at 48C. The immunoprecipitated pellets were washed four times with lysis buffer (see above) and finally resuspended in SDS sample buffer. The immunoprecipitates were subjected to SDS ± PAGE and transferred onto a nitrocellulose membrane. Western blot analysis was performed as described previously with horseradish peroxidase-conjugated rabbit anti-mouse (for the detection of GFP and caspase-7) (DAKO) or goat anti-rabbit (for the detection of caspase-2, -3, -8, -9, -10 and cleaved forms of caspase-8 and -9) (Sigma) immunoglobulins. 5 The proteins were visualized by using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech).
Apoptosis assays
IGROV-EQ56 cells were transfected with either pFLAG-Casp8(C/S) or a control vector pCI-FLAG. Sixteen hours after transfection, the expression of EGFP-polyQ 56 was induced by removing tetracycline (TC) from the medium. z-VAD-fmk (50 mM) was added to some cells after transfection. Two days after induction, cells were stained with the DNA dye Hoechst33342 (1.25 mM, 10 min). Cells expressing EGFPpolyQ 56 were scored as apoptotic when they had a pyknotic and/or fragmented nucleus. Apoptotic nuclei were counted in a blinded manner.
